Researcher Spotlight: Harsh Shah, DO THE UNIVERSITY OF UTAH Immunotherapy with checkpoint inhibitors is commonly used for treatment of Hodgkin lymphoma after relapse. While many patients initially respond to these therapies, the development of resistance is common over time. Dr.…
Researcher Spotlight: Harsh Shah, DO THE UNIVERSITY OF UTAHStedman Family Scholar The future of lymphoma treatment is rapidly evolving, and investigator-initiated clinical trials are helping to pave the way toward improved treatment approaches. Dr. Shah’s LRF research is focused on…
Researcher Spotlight: Natalie Grover, MD The University of North Carolina at Chapel Hill Although a majority of patients with Hodgkin lymphoma (HL) are cured with first-line therapy; about 15 percent of those patients experience primary refractory disease or relapse after…
Researcher Spotlight: Anita J. Kumar, MD, MSCE Tufts Medical Center For most Hodgkin lymphoma (HL) patients, chemotherapy is the standard treatment. However, patients often have their initial treatment plan modified (through dose adjustment or delays in treatment) due to concerns…
Researcher Spotlight: Justine M. Kahn, MD Columbia University Medical Center Dr. Kahn is Instructor of Pediatrics at Columbia University Medical Center. Her Lymphoma Clinical Research Mentoring Program (LCRMP) project analyzes racial and ethnic disparities in the survival rates of…
Researcher Spotlight: Hema Dave, MD Children’s Research Institute (Children’s National Medical Center) Dr. Dave is Assistant Professor of Pediatrics, Children’s National Health System, The George Washington School of Medicine and Health Sciences. Her Lymphoma Clinical Research Mentoring Program (LCRMP)…